Insider · CIK 0001793971
Aurora Daljit Singh
officer
Files at NMRA (Neumora Therapeutics, Inc.). First filing Feb 20, 2025, latest Feb 20, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $14k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | $14k | 8,565 | -9% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | NMRA Neumora Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,565 | $1.68 | $14k | 88,935 | Feb 20, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,000,000 | $0.00 | $0 | 1,000,000 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,890 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnote | -137,538 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -207,901 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnote | -136,210 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -72,221 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: See footnote | -29,737 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -195,000 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,890 | - | - | 40,890 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +137,538 | - | - | 137,538 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +207,901 | - | - | 207,901 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +136,210 | - | - | 136,210 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +72,221 | - | - | 72,221 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +29,737 | - | - | 29,737 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +195,000 | - | - | 195,000 | Feb 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.